dc.relation.reference | 1. Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ and Holland PV. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med 1975; 292, 767-70.
2. Choo QL, Kuo G, Weiner AJ et al. Isolation of a cDNA clone derived from a blood born non-A,non-B viral hepatitis genome. Science 1989; 244, 359-62.
3. Kuo G, Choo QL, Alter HJ et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244, 362-4.
4. Thomson BJ and Finch RG. Hepatitis C virus infection. Clin Microbiol Infect 2005; 11: 86-94.
5. Sun CA, Chen HC, Lu CF et al. Transmission of hepatitis C viral in Taiwan: Prevalence and risk factors based on a nationwide survey. J Med Virol 1999; 59, 290-6.
6. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26: 62S-65S.
7. Alter MJ and Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994; 23: 437-55.
8. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 26: 15S-20S.
9. Seeff LB. Nature history of hepatitis C. Hepatology 1997; 26: 21S-28S.
10. Kato JH, Hijikata M, Ootsuyama Y et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 1990; 87, 9524-8.
11. Choo QL, Richman KH, Han JH et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA 1991; 88, 2451-5.
12. Kaito M, Watanabe S, Tsukiyama-Kohara K et al. Hepatitis C virus particle detected by immunoelectron microscopic study. J Gen Virol 1994; 75, 1755-60.
13. Shimizu YK, Feinstone SM, Kohara M and Yoshikura H. Hepatitis C virus: detection of intracellular virus particles by electron microscopy. Hepatology 1996; 23, 2005-9.
14. Mizuno M, Yamada G, Tanaka T et al. Virion-like structure in Hela G cells transfected with the full length sequence of the hepatitis C virus genome. Gastroenterology. 1995; 109,1933-40.
15. Penin F, Dubuisson J, Rey FA, Moradpour D and Pawlotsky JM. Structure biology of hepatitis C virus. Hepatology 2004; 39: 5-19.
16. Grakoui A, Wychowski C, Lin C and Rice CM. Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 1993; 67, 1385-95.
17. Grakoui A, McCourt DW, Wychowski C and Rice CM. A second hepatitis C virus encoded proteinaase. Proc Natl Acad Sci USA 1993; 90, 10583-7.
18. Hijikata M, Mizushima H, Tanji Y et al. Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. Proc Natl Acad Sci USA 1993; 90, 10773-7.
19. Tomei L, Failla C, Santolini E and La Monica N. NS3 is a serine protease require for processing of hepatitisC virus polyprotein. J Virol 1993; 67, 4017-26.
20. Simmonds P, Alberti A, Alter HJ et al. A propose system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19, 1321-4.
21. Simmonds P, Rose KA, Graham S et al. Mapping of serotype-specific peptides to serologically differentiate infections with HCV type 1,2 and 3. J Clin Microbiol 1993; 31, 1493-503.
22. Kao JH, CheN PJ, Lai MY et al. Genotypes of hepatitis C virus in Taiwan and the progression of liver disease. J Clin Gastrorenterol 1995; 21, 233-7.
23. Wu CH, Lee MF and Kao HS. Distribution of hepatitis C virus genotypes among blood donors in Taiwan. J Gastroenterrol Hepatol 1997; 12: 625-8.
24. Chamberlain RW, Adams N, Saeed AA et al. Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant genotype in the Meddile East. J Gen Virol 1997; 78, 1341-7.
25. Tsukiyama KK, Iizuka N, Kohara M and Nomoto A. Internal ribosome entry site within hepatitis C virus RNA. J Virol 1992; 66, 1476-83.
26. Brown EA, Zhang H, Ping LH and Lemon SM. Secondary structure of the 5’ nontranslated region of hepatitis C virus and pestivirus genomic RNAs. Nucleic Acides Res 1992, 20, 5041-5.
27. Honda M, Beard MR, Ping LH and Lemon SM. A phylogenetically conserved stem-loop structure at the 5’ border for cap-independent viral translation. J Virol 1999; 73, 1165-74.
28. Smith DB, Mellor J, Jarvis LM et al. Variation of the hepatitis C virus 5’-noncoding region: implication for secondary structure, virus detection and typing. J Gen Virol 1995; 76, 1749-61.
29. Sizova DV, Kolupaeva VG, Pestova TV and Hellen CU. Specific interaction of eukaryotic translation initiation factor 3 with the 5’ nontranslated region of the hepatitis C virus and classical swine fever virus RNA. J Virol 1998; 72: 4775-82.
30. Tanaka T, Kato N, Cho MJ and Shimoyohno K. A novel sequence found at the 3’ terminus of hepatitis C virus genome. Biochem Biophys Res Commun 1995; 215, 744-9.
31. Yamada N, Tanihara K, Takada A et al. Genetic organization and diversity of the 3’ noncoding region of the hepatitis C virus genome. Virology 1996; 223, 255-61.
32. Tanaka T, Kato N, Cho MJ, Suguyama K and Shimoyohno K. Structure of the 3’ terminus of hepatitis C virus genome. J Virol 1996; 70, 3307-12.
33. Kolykhalov AA, Feinstone SM and Rice CM. Identification of a highly conserved sequence element at the 3’ terminus of hepatitis C virus genome RNA. J Virol 1996; 70, 3363-71.
34. Blight KJ and Rice CM. Secondary structure determination of the conserved 98-base sequence at the 3’ terminus of hepatitis C virus genome RNA. J Virol 1997; 71, 7345-52.
35. Tsuchihara K, Tanaka T, Hijikata M et al. Specific interactionof polypyrimidine tract-binding protein with the extreme 3’-terminus structure of the hepatitis C virus genome, the 3’X. J Virol 1997; 71, 6720-6.
36. Ito T, Tahara SM and Lai MM. The 3’-untranslated region of hepatitis C virus RNA enhances translation from an internal ribosomal entry site. J Virol 1998; 72, 8789-96.
37. Gontarek RR, Gutshall LL, Herold KM et al. hnRNP C and polypyrimidine tract-binding protein specific interact with the pyrimidine rich region within the 3’NTR of the HCV RNA genome. Nucleic A cids Res 1999; 27: 1457-63.
38. Chung RT and Kaplan LM. Heterogeneous nuclear ribonucleoprotein I selectively binds the conserved 3’ terminus of hepatitis C viral RNA. Biochem Biophy Res Commun 1999; 254: 351-62.
39. Harada S, Watanabe Y, Takeuchi K et al. Expression of processed core protein of hepatitis C virus in mammalian cells. J Virol 1991; 65, 3015-21.
40. Lin Q, Tackney C, Bhat RA and Zhang P. Regulated processing of the hepatitis C virus core protein is linked to subcellular localization. J Virol 1997;71, 657-62.
41. Yasui K, Wakita T, Tsukiyama KK et al. The native form and maturation process of hepatitis C virus core protein. J Virol 1998; 72, 6048-55.
42. Shih CM, Lo SJ, Miyamura T and Lee YH. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in Huh-7 cells. J Virol 1993; 67, 5823-32.
43. Suzuki R, Matsuura Y, Suzuki T et al. Nuclear localization of the truncated hepatic C virus core protein with the hydrophobic C terminus deleted. J Gen Virol 1995; 76, 53-61.
44. Nasoff MS, Zebedee SL,Inchauspe G and Prince AM. Identification of an immunodominant epitope within the capside protein of hepatitis C virus. Proc Natl Acad Sci USA. 1991; 88: 5462-66.
45. Moryia K, Shintani Y, Yotsuyanagi H,et al. The core protein of hepatitis C virus induce hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4, 1065-7.
46. Ray RB, Lagging LM, Meyer K and Ray R. Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigeneic phenotype. J Virol 1996; 70, 4438-43.
47. Chen CM, You LR, Hwang LH and Lee YH. Direct interaction of hepatitis C virus core protein with the cellular lymphotoxin-beta receptor modulates the signal pathway of the lymphotoxin-beta receptor. J Virol 1997; 71, 9417-26.
48. Matsumoto M, Hsieh TY, Zhu N et al. Hepatitis C virus core protein interact with the cytoplasmic tail of lymphotoxin –beta receptor. J Virol 1997, 71, 1301-9.
49. Zhu N, Khoshnan A, Schneider R, Ware C and Lai MM. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis f actor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol 1998; 72, 3691-7.
50. Ruggieri A, Harada T, Matsuura Y and Miyamura T. Sensitization to Fas- mediated apoptosis by hepatitis C virus core protein. Virology 1997; 229, 68-76.
51. Ray RB, Steele R, Meyer K et al. Inhibition of tumor necrosis factor mediated apoptosis by hepatitis C virus core protein. J Biol Chem 1998; 273, 2256-9.
52. Miyamura T and Matsuura Y. Structural proteins of hepatitis C virus. Trends Microbiol 1993; 1, 229-31.
53. Weiner AJ, Brauer MJ, Rosenblatt J et al. Variable and hypervariable domains are found in the region of HCV corresponding to the flavivirus envelope and NS proteins and the pestivirus envelope glycoprotein. Virology 1991; 180, 842-8.
54. Kato JH, Ootsuyama Y, Ohkoshi S et al. Characterization of hypervariable regions in the putative envelope protein of hepatitis C virus. Biochem Biophys Res Commun 1992; 189, 119-27.
55. Grakoui A, McCourt DW, Wychowski C, Feinstone SM and Rice CM. Characterization of the hepatitis C virus encode serine protease: determination of proteinase-dependent polyprotein cleavage sites. J Virol 1993; 67: 2832-43.
56. Taylor DR, Shi ST, Romano PR, Barber GN and Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999; 285, 107-10.
57. Varakioti A, Vassilaki N,Georgopoulou U and Mavromara P. Alternate translation occurs within the core coding region of the hepatitis C viral genome. J Biol Chem 2002; 277: 17713-21.
58. Xu Z, Choi J, Yen TS et al. Synthesis of a novel hepatitis C virus protein by ribosomal frameshift. ENBO J 2001; 20: 3840-48.
59. Carrere-Kermer S, Montpellier-Pala C, Cocquerel L et al. Subcellular localization and topology of the p7 polypeptide of hepatitis C virus. J Virol 2002; 76: 3720-30.
60. Pavlovic D, Neville DC, Argaud O et al. The hepattis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc Natl Acad Sci USA 2003; 100: 6104-08.
61. Grakoui A, McCourt DW, Wychowski C and Rice CM. Characterization of the hepatitis C virus encoded serine protease: determination of protease dependent polyprotein cleavage sites. J Virol 1993; 67, 2832-43.
62. D’Souza ED, O’Sullivan E, Amphlett EM et al. Analysis of NS3- mediated processing of the hepatitis C virus non-structural region in vitro. J Gen Virol 1994; 75, 3469-76.
63. Manabe S, Fuke I, Tanishita O et al. Production of nonstructural protein of hepatitis C virus require a putative viral protease encoded by NS3. Virology 1994; 198, 636-44.
64. Lin C, Pragai BM, Grakoui A, Xu J and Rice CM. Hepatitis C virus NS3 serine protease: trans-cleavage requirements and processing kinetics. J Virol 1994; 68, 814-57.
65. Love RA, Parge HE, Wickersham JA et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 1996; 87, 331-42.
66. Jin L and Peterson DL. Expression, isolation and characterization of hepatitis C virus ATPase/RNA helicase. Arch Biochem Biophys 1995; 323, 47-53.
67. Borowski P, Heiland M, Feucht H and Laufs L. Characterization of non-structure protein 3 of hepatitis C virus as modulator of protein phosphorylation mediated by PKA and PKC: evidence for action on the level of substrate and enzyme. Arch Virol 1999; 144, 687-701.
68. Asabe SI, Tanji Y, Satoh S et al. The N-terminal region of hepatitis C virus encoded NS5A is important for NS4A-dependent phosphorylation. J Virol 1997; 71, 790-6.
69. Hugle T, Fehrmann F, Bieck E et al. The hepatitis C virus nonstructure protein 4B is an integral endoplasmic reticulum membrane protein. Virology 2001; 284: 70-81.
70. Ludin M, Monne M, Widell A, Von Heijne G and Persson MA. Topology of the membrane associated hepatitis C virus protein NS4B. J Virol 2003; 77: 5428-38.
71. Egger D, Wolk B, Gosert R et al. Expression of hepatitis C virus protein s induces distinct membrane alterations including a candidate viral replication complex. J Virol 2002; 76: 5974-84.
72. Gao L, Aizaki H, He JW and Lai MM. Interactions between viral nonstructural proteins and host protein Hvap-33 mediated the formation of hepatitis C virus RNA replication complex on lipid raft. J Virol 2004; 78: 3480-88.
73. Moradpour D, Gosert R, Egger D et al. Membrane associated of hepatitis C virus nonstructural proteins and identification of the membrane alteration that harbors the viral replication complex. Antiviral Res 2003; 60: 103-9.
74. Tanji Y, Kaneko T, Satoh S and Shimoyohno K. Phosphorylation of hepatitis C virus encode nonstructural protein NS5A. J Virol 1995; 69, 3980-6.
75. Reed KE, Xu J and Rice CM. Phosphorylation of the hepatitis C virus NS5A protein in vitro and in vivo: properties of the NS5A- associated kinase. J Virol 1997; 71, 7187-97.
76. Macdonald A, Crowder K, Street A et al. The hepatitis C virus non-structural NS5A protein inhibits activating protein-1 function by perturbing ras-ERK pathway signaling. J Biol Chem 2003; 278: 1775-84.
77. Street A, Macdonald A, Crowder K and Harris M. The hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase dependent survival signaling cascade. J Biol Chem 2004; 279: 12232-41.
78. Gale MJ, Blakely CM, Kwieciszewski B, Tan SL et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998; 18, 5208-18.
79. Hwang SB, Park KJ, Kim YS and Lai MM. Hepatitis C virus NS5B protein is a membrane associated phosphoprotein with a predominantly perinuclear localization. Virology 1997; 227, 439-46.
80. Behrens SE, Tomei L and De Francesco R. Identification and properties of the RNA-dependent-RNA polymerase of hepatitis C virus. EMBO J 1996; 15, 12-22.
81. Lohmann V, Korner F, Herian U and Bartenschlager R. Biochemical properties of hepatitis C virus NS5B RNA dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J Virol 1997; 71, 8416-28.
82. Ishii K, Tanaka Y, Yap CC et al. Expression of hepatitis C virus NS5B protein: characterization of its RNA polymerase activity and RNA binding. Hepatology 1999; 29, 1227-35.
83. Ishido S, Fujita T and Hotta H. Complex formation of NS5B with NS3 and NS4A proteins of hepatitis C virus. Biochem Biophys Res Commun 1998; 244, 35-40.
84. Pileri P, Uematsu Y, Campagnoli S et al. Binding of hepatitis C virus to CD81. Science 1998; 282: 938-41.
85. Scarselli E, Ansuini H, Cerino R et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002; 21: 5017-25.
86. Evans MJ, von Hahn T, Tscheme DM et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007; 446: 801-7.
87. Germi R, Crance JM,Garin D et al. Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. J Med Virol 2002; 68: 206-15.
88. Brentner M. Existing and future therapeutic options for hepatitis C virus infection. Acta Biochem Pol 2005; 52: 57-70.
89. Gale MJ and Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005; 436: 939-45.
90. Yoneyama M, Kikuchi M, Natsukawa T et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004; 5: 730-7.
91. Alexopoulon L, Holt AC, Medzhitov R et al. Recognition of double-stranded RNA and activation of NFκB by Toll-like receptor 3. Nature 2001; 413: 732-8.
92. Akira S and Takeda K. Toll-like receptoe signaling. Nat Rev Immunol 2004; 4: 499-511.
93. Mercer DF, Schiller DE, Elliott JF et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7: 927-33.
94. Zhong J, Gas LP, Cheng G et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2005; 102: 9294-9.
95. Lohmann V, Korner F, Koch J et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-3.
96. Wakita T, Pietschmann T, Kato T et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2007; 11: 791-6.
97. Feld JJ and Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005, 436, 967-73
98. Wang YS, Youngster S, Grace M, Bausch J, Bordens R and Wyss DF. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implication. Adv Drug Deliv Rev 2002; 54: 547-70.
99. Peter M. Mechanisms of action of interferons. Semin Liver Dis 1989; 9, 235-9.
100.Gilmour KC and Reich NC. Signal transduction and activation of gene transcription by interferon. Gene Expr 1995; 5: 1-18.
101.Gale MJ. Effector genes of interferon action against hepatitis C virus. Hepatology 2003; 37: 975-8.
102. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14: 778-809.
103. Stark GR, Kerr IM, Williams BRG, Silverman RH and Schreiber RD. Hoe cells response to interferon. Annu. Rev. Biochem 1998; 67, 227-64.
104. Williams B.RG. PKR; a sentinel kinase for cellular stress. Oncogene 1999; 18: 6112-20.
105. Malathi K, Paranjape MJ, Bulanova E, et al. A transcriptional signaling pathway in the IFN system mediated by 2’-5’-oligoadenylate activation of RNase L. Proc Natl Acad Sci U.S.A. 2005; 102: 14533-38.
106. Patterson JL and Fernandez-Larsson R. Molecular mechanism of action of ribavirin. Rev Infect Dis 1990; 12, 1139-46.
107. DiBisceglie AM and Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology 2002; 36: S121-7.
108. Sidewell RW, Robins RK and Hillyard IW. Ribavirin: an antiviral agent. Pharmacol Ther 1979; 6: 123-46.
109. Lai MY, Kao JH, Yang PM et al. Long term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111, 1307-12.
110. Willis RC, Carson DA and Seegmiller JE. Adenosine kinaseinitiates the major route of ribavirin activation in a cultured human cell line. Proc Natl Acad Sci USA 1978; 75: 3042-44.
111. Lau JY, Tam RC, Liang TJ and Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35: 1002-09.
112. Hager PW, Collart FR,Huberman E and Mitchell BS. Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding. Biochem Pharmacol 1995; 49: 1323-29.
113. Sintchak MD and Nimmesgern E. The structure of inosine 5’-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology 2000; 47: 163-84.
114. McHutchison JG, Shiffman ML, Cheung RC et al. A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C. Antivir Ther 2005; 10: 635-43.
115. Hezode CM, Bouvier-Alias C, Costentin F et al. Effect of an IMPDH inhibitor, merimepodib(MMPD), assessed alone and in combination with ribavirin, on HCV replication: implication regarding ribavirin’s mechanisms of action. Hepatology 2006; 44(Suppl 1): 615A.
116. Malinoski F and Stollar V. Inhibitors of IMP dehydrogenases prevent sindbis virus replication and reduce GTP levels in Aedes albopictus cells. Virology 1981; 110: 281-91
117. Maag D, Castro C, Hong Z and Cameron CE. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 2001; 276: 46094-098
118. Vo NV, Young KC and Lai MM. Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase. Biochemistry 2003; 42: 10462-71.
119. Crotty S, Maag D, Arnold JJ et al. The broad spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000; 6: 1375-79.
120. Crotty S, Cameron CE and Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci USA 2001; 98: 6895-900.
121. Lanford RE, Chavez D, Guerra B et al. Ribavirin induces error prone replication of GBV-B in primary tamarin hepatocytes. J Virol 2001; 75: 8074-81.
122. Pawlotsky JM, Dahari H, Neumann AU, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004; 126: 703-14.
123. Lutchman GA, Liang TJ, Hoojnagl JH et al. Mutation rate of hepatitis C virus in patients during ribavirin monotherapy. Hepatology 2004; 41: 385A.
124. Tam RC, Pai B, Bard J, et al. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J Hepatol 1999; 30: 376-82.
125. Fang SH, Lai MY, Hwang LH, et al. Ribavirin enhances interferon-γlevels in patients with chronic hepatitis C treated with interferon-α. J Biomed Sci 2001; 8: 484-91.
126. Mosmann TR and Coffman RL. TH1 and TH2 cells: different patterns of lymphocyte secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145-73.
127. Rehermann B and Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nature Rev Immunol 2005; 5: 215-29.
128. Tam RC, Ramasamy K, Bard J, Pai B, Lim C. and Averett DR. The ribavirin analog ICN 17261 demonstrates reduced toxicity and antiviral effects with retention of both immunomodulatory activity and reduction of hepatitis-induced serum alanine aminotransferase levels. Antimicrob Agents Chemother 2000; 44: 1276-83.
129. Pockros PJ, Pessoa MG., Diago M, et al. Combination of levovirin (LVV) and peginterferon alfa-2a fails to generate a virological response comparable to ribavirin (RBV) and peginterferon alfa-2a in patients with chronic hepatitis C. Hepatology 2004; 40(Suppl 1): 391A.
130. Rivas-Estilla AM, Svitkin Y, Lastra ML, Hatzoglou M, Sherker A, and Koromilas AE. PKR-dependent mechanisms of gene expression from a subgenomic hepatitis C virus clone. J Virol 2002; 76: 10637-53.
131. Zhang Y, Jamaluddin M, Wang S, et al. Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial Cells. J Virol 2003; 77: 5933-47.
132. Strader DB, Wright T, Thomas DL and Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39, 1147-71.
133. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36(Suppl 1), S35-S46.
134. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352, 1426-32.
135. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339, 1485-92.
136. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358, 958-65.
137. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347, 975-82.
138. McNair ANB and Kerr IM. Viral inhibition of the interferon system. Pharmacol Ther 1992; 56, 79-95.
139. Clarke PA, Schwemmle M, Schichinger J, Hilse K and Clemens MJ. Binding of Epstein Barr virus small RNA EBER-1 to the double stranded RNA activated protein kinase DAI. Nucl Acid Res 1991; 19, 243-48.
140. Davies MV, Elroy-Stein O, Jagus R and Kaufman RJ. The vaccinia virus K3L gene product potentate’s translation by inhibiting double stranded RNA activated protein kinase and phosphorylation of the alpha subunit of eukaryotic initiation factor 2. J Virol 1992; 66, 1943-51.
141. Black TL, Safer B, Hovanessian A and Katze M. The cellular 68,000-Mr protein kinase in highly autophosphorylation and activated yet significantly degrade during poliovirus infection; implication for translation regulation. J Virol 1989; 63, 2244-51.
142. Wood JN and Hovanessian AG. Interferon enhances 2-5A synthetase in embryonal carcinoma cells. Nature 1979; 74-6.
143. Rivier Y and Hovanessian AG. Direct action of interferon and inducers of interferon on tumor cells in a thymic nude mice. Cancer Res 1983; 43, 4596-99.
144. Meurs EF, Chong K, Galabru J et al. Molecular cloning and characterization of the human double stranded RNA activated protein kinase induced by interferon. Cell 1990; 62, 379-90.
145. Koromials AE, Roy S, Barber GN, Katze MG and Sonenberg N. Malignant transformation by a mutant of the IFN-inducible dsRNA dependent protein kinase. Science.1992; 257, 1685-89.
146. Katze MG, Wambach M, Wong ML et al. Function expression and RNA binding analysis of interferon-induced, double stranded RNA activated 68000-Mr protein kinase in a cell-free system. Mol Cell Biol 1991; 11, 5494-505.
147. Green SR and Mathewss MB. Two RNA-binding motifs in the double stranded RNA activated protein kinase, DAI. Genes Devel 1992; 6, 2478-90.
148. Chong KL, Feng L, Schappert K et al. Human p68 kinase exhibits growth suppression in yeast and homology to the translational regulator GCN2. EMBO J 1992; 11, 1553-82.
149. Romano PR, Garcia-Barrio MT, Zhang X, et al. Autophosphorylation in the activation loop is required for full kinase activity in vivo of human and yeast eukaryotic initiation factor 2 kinase PKR and GCN2. Mol Cell Biol 1998; 18: 2282-97.
150. Meurs EF, Galabru J, Barber GN, Katze MG and Hovanessian AG. Tumor suppressor function of interferon-induced, double stranded RNA activated protein kinase. Proc Natl Acad Sci USA 1993; 90, 232-36.
151. Lee SB and Esteban M. The interferon-induced, double stranded RNA activated protein kinase induces apoptosis. Virol 1994; 199, 491-6.
152. Balachandran S, Roberts P, Brown LE, et al. Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity 2000; 13: 129-41.
153. Fulvio A and Sankar G. PACT and PKR: Turning on NF-κB in the absence of virus. Sci STKE 2001; 89: 1-4.
154. Rekha CP and Ganes CS. PACT, a protein activator of the interferon-induced protein kinase, PKR. EMBO J 1998; 17: 4379-90.
155. Li S, Peter GA, Ding K, Zhang X, Qin J and Ganes CS. Molecular basis for PKR activation by PACT or dsRNA. Proc Natl Acad Sci USA 2006; 103: 10005-10.
156. Patel CV, Handy I, Goldsmith T and Patel RC. PACT, a stress-modulated cellular activator of interferon-induced double-stranded RNA-activated protein kinase, PKR. J Biol Chem 2000; 275: 37993-98.
157. Dixit NM, Layden-Almer JE, Layden TJ and Perelson AS. Modeling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2005; 432: 922-24.
158. Chen HL, Wu HL, Chen PJ, Lai MY and Chen DS. Long-term culture of hepatocytes from human adults. J Biomed Sci 1998; 5: 435-40.
159. Ikeda M, Yi MK, Li K and Lemon SM. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh-7 cells. J Virol 2002; 76: 2997-3006.
160. Sarbassov DD, Guertin DA, Ali SM and Sabatini DM. Phosphorylation and regulation of Akt/PKB by the Rictor-mTOR complex. Science 2005; 307: 1098-101.
161. Hu Y and Conway TW. 2-aminopurine inhibits the double-stranded RNA-dependent protein kinase both in vitro and in vivo. J Interferon Res 1993; 13: 323-28.
162. Lemaire PA., Lary J and Cole JL. Mechanism of PKR activation: Dimerization and kinase activation in the absence of double-stranded RNA. J Mol Biol 2005; 345: 81-90.
163. Gabel F, Wang D, Madern D, et al. Dynamic flexibility of double-stranded RNA activated PKR in solution. J Mol Biol 2006; 359: 610-23.
164. Hochstrasser M. Ubiquitin dependent protein degradation. Annu Rev Genet 1996; 30: 405-439.
165. Varshavsky A. The ubiquitin system. Trends Biochem Sci 1997; 22: 383-387.
166. Ciechanover A. The ubiquitin proteasome pathway: on protein death and cell life. EMBO J 1998; 17: 7151-7160.
167. Maki CG, Huibregtse JM and Howley PM. In vivo ubiquitination and proteasome mediated degradation of p53. Cancer Res1996; 56:2649-2654.
168. Wang C, Pflugherber J, Smter R, et al. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol 2003; 77: 3898-912.
169. Chang KS, Cai Z, Zhang C, Sen GC, Williams BRG and Luo G. Replication of hepatitis C virus (HCV) RNA in mouse embryonic fibroblasts: Protein kinase R (PKR) - dependent and PKR-independent mechanisms for controlling HCV RNA replication and mediating interferon activities. J Virol 2006; 80: 7364-74.
170. Guo JT, Zhu Q and Seeger C. Cytopathic and noncytopathic interferon responses in cells expressing hepatitis C virus subgenomic replicons. J Virol 2003; 77: 10769-779.
171. Pawlotsky JM, Dahari H, Neumann AU, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004; 126: 703-14.
172. Tsubota A, Hirose Y, Izumi N and Kumada H. Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. Br J Clin Pharmacol 2003; 55: 360-7.
173. Tanbae Y, Sakamoyo N, Enomoto N, et al. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-α. J Infect Dis 2004; 189: 1129-39.
174. Dixit NM, Layden-Almer JE, Layden TJ and Perelson AS. Modeling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004; 432: 922-24.
175. Neumann AU, Lan NP, Dahari H, et al. Hepatitis C viral dynamic in vivo and the antiviral efficacy of interferon-α therapy. Science 1998; 282: 103-7.
176. Jen JF, Glue P, Gupta S, Zambas D and Hajian G. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000; 22: 555-65.
177. Herrmann E, Lee JH, Marinos G, Modi M and Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003; 37: 1351-58
178. Wilkins MR, Williams KL, Appel RD, Hochstrasser DF. Proteome Rearch: New Frontiers in Functional Genomics. New York: Spring-Verlag Berlin Heidelbug, 1997
179. Wasinger VC, Cordwell SJ, Cerpa-Poljak A, et al. Progress with gene-product mapping of the mollicutes: Mycoplasma genitalium. Electrophoresis 1995; 16: 1090-94.
180. Molloy MP. Two-dimensional electrophorsis of membrane protein using immobilized pH gradient. Anal Biochem 2000; 280: 1-10.
181. Roepstorff P. Mass spectrometry in protein studies from genome to function. Curr Opin Biotechol 1997; 8: 6-13.
182. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995; 270: 467-70.
183. Bertucci F, Bernard K, Loriod B, et al. Sensitivity issues in DNA array-based expression measurements and performance of nylon microarrays for small samples. Hum Mol Genet 1998; 8: 1715-22.
184. Chen JJW, Wu R, Yang PC, et al. Profiling expression patterns and isolating differentially expressed genes by cDNA microarray system with colorimetry detection. Genomics 1998; 51: 313-24.
185.Chen HW, Chen JJW, Tzeng CR, et al. Global analysis of differentially expressed genes in early gestational deciduas and chronic villi using a 9600 human cDNA microarray. Mol Hum Reprod 2002; 8: 475-84.
186. Sargsyan E, Baryshev M, Szekely L, Sharipo A and Mkrtchian S. Identificationof ERp29,an endoplasmic reticulum luminal protein as a new member of the thyroglobulin folding complex. J Biol Chem 2002; 277: 17009-15.
187. Janssen U, Fink T, Lichter P and Stoffel W. Human mitochondrial 3,2-trans-enoyl-CoA isomerase (DCI): Gene structure and localization to chromosome 16p13.3. Gemomic 1994; 23: 223-228.
188. Whitbread AK, Masoumi A, Tetlow N, et al. Characterization of the omega class of glutathione transferase. Methods Enzymol 2005; 401: 78-99.
189. Hayea JD, Flanagan JU and Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005; 45: 51-88.
190. Zakharyan RA, Sampayo RA, Healy SM, et al. Human monomethylarsonic acid (MMA(V)) reductase is a member of the glutathione-S-transferase superfamily. Chem Res Toxicol 2001; 14: 1051-57.
191. Jay P, Ji JW, Marsollier C. et al. Cloning of the human homologue of the TGF beta-stimulated clone 22 gene. Biochem Biophys Res Commun 1996; 222: 821-26.
192. Vinal F and Pouyssegur J. Transforming growth factor β1 (TGF-β1) promotes endothelial cell survival during in vitro angiogenesis via an autocrim mechanism implicating TGF-α signaling. Mol Cell Biol 2001; 21: 721-30.
193. Hellmich MR, Pant HC, Wada E and Battey JF. Neuronaal cdc2-like kinase: a cdc2-related protein kinase with predominantly neuronal expression. Proc Natl Acad Sci USA 1992; 89: 10867-71.
194. Xiong Y, Zhang H and Beach D. Dtype cyclin associate with multiple protein kinase and the DNA replication and repair factor PCNA. Cell 1992; 71: 505-14.
195. Zheng M, Leung CL and Liem RK. Region specific expression of cyclin dependent kinase 5 (cdk5) and its activators, p35 and p39 in the developing and adult rat central nervous system. J Neurobiol 1998; 35: 141-59.
196. Musa FR, Tokuda M, Kuwata Y et al. Expression of cyclin-dependent kinase 5 and associated cyclins in Leydig and Sertoli cells of the testis. J Androl 1998; 19: 657-66.
197. LinH, Chen MC, Chiu CY, Song YM and Lin SY. Cdk5 regulates STAT3 activation and cell proliferation in medullary thyroid carcinoma cells. J Biol Chem 2007; 282: 2776-84.
198. Meek DW. Multisite Phosphorylation and the Integration of Stress Signals at p53. Cell Signal 1998; 10: 159-66.
199. Lee JC, Shih YF, Hsu SP et al. Development of a cell-based assay for monitoring specific hepatitis C virus NS3/4A protease activity in mammalian cells. Analytical Biochemistry 2003; 316: 162-70. | en |